TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB

被引：0
|
作者：
Abou-Alfa, G. K. [1 ]
Zhao, B. [1 ]
Capanu, M. [1 ]
Guo, P. [1 ]
Liu, F. [1 ]
Jacobs, G. [1 ]
Gansukh, B. [1 ]
Moscovici, M. [2 ]
Lentini, G. [3 ]
Schwartz, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bayer SpA PH, Med, Milan, Italy
[3] Bayer Vital GmbH, Gi Oncol, Leverkusen, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [21] Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib
    Fonseca, L. G. D.
    Diaz, A.
    Sapena, V.
    Diaz-Gonzalez, A.
    Boix, L.
    Sanduzzi-Zamparelli, M.
    Fuster, C.
    Llarch, N.
    Iserte, G.
    Torres, F.
    Bruix, J.
    Reig, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 238 - 238
  • [22] Concomitant use of antiacids in patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib therapy
    Razak, Razwan Abd
    Kunene, Victoria
    Ma, Yuk Ting
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Finn, R. S.
    Poon, R. T. P.
    Yau, T.
    Klumpen, H.
    Chen, L.
    Kang, Y.
    Kim, T.
    Gomez-Martin, C.
    Rodriguez-Lope, C.
    Kunz, T.
    Paquet, T.
    Asubonteng, K.
    Winkler, R. E.
    Anak, O.
    Sellami, D. B.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Early experience of combination treatment of sorafenib and radiotherapy in patients with advanced hepatocellular carcinoma (HCC)
    Seong, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [25] Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC)
    Kim, R. D.
    Byrne, M. T.
    Hammel, J.
    El-Gazzaz, G.
    Aucejo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Serum mass spectrometry analysis in hepatocellular carcinoma (HCC) patients treated with sorafenib (S)
    Chelis, L.
    Kakolyris, S.
    Mimidis, K.
    Xenidis, N.
    Amarantidiss, K.
    Meyer, K.
    Roder, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S466 - S466
  • [27] Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma
    Williet, Nicolas
    Clavel, Lea
    Bourmaud, Aurelie
    Verot, Celine
    Bouarioua, Nadia
    Roblin, Xavier
    Merle, Philippe
    Phelip, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (09) : 1043 - 1049
  • [28] Changes of Cytokines in Cirrhosis Patients With Advanced Hepatocellular Carcinoma Treated by Sorafenib
    Nagai, Hidenari
    Mukozu, Takanori
    Matui, Daigo
    Ogino, Yu
    Kanekawa, Takenori
    Kogame, Michio
    Takayama, Ryuji
    Kanayama, Masahiro
    Wakui, Noritaka
    Shinohara, Mie
    Shinohara, Masao
    Ishii, Koji
    Igarashi, Yoshinori
    Sumino, Yasukiyo
    GASTROENTEROLOGY, 2012, 142 (05) : S979 - S979
  • [29] Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib
    Antonelli, G.
    Gigante, E.
    Iavarone, M.
    Begini, P.
    Biondetti, P.
    Pellicelli, A. M.
    Sangiovanni, A.
    Lampertico, P.
    Marignani, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S207 - S208
  • [30] The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib
    Sarpel, Umut
    Spivack, John H.
    Berger, Yaniv
    Heskel, Marina
    Aycart, Samantha N.
    Sweeney, Robert
    Edwards, Martin P.
    Labow, Daniel M.
    Kim, Edward
    HPB, 2016, 18 (05) : 411 - 418
12345